ERYTHROCIN LIQ 250 DIN 00273023
Health Canada record
| Active ingredient(s) | ERYTHROMYCIN STEARATE 50 MG |
|---|---|
| Dosage form | Liquid |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01FA01 ERYTHROMYCIN |
| Original market date | 31-Dec-1973 |
| Current status date | 12-Jun-2006 |
| Source | Health Canada DPD |
Establishment licence of the holder
Abbott Laboratories Co. — licence 3-002635, currently licensed, last inspection rating C (2024-09-23).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ERYTHROMYCIN STEARATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00704393 | ERYTHRO-500 TAB 500MG USP | PRO DOC LIMITEE | Tablet | ERYTHROMYCIN STEARATE 500 MG | Cancelled Post Market |
| 00000302 | ERYTHROCIN LIQUID 125 | ABBOTT LABORATORIES, LIMITED | Liquid | ERYTHROMYCIN STEARATE 25 MG | Cancelled Post Market |
| 00563854 | ERYTHROMYCINE 250 TAB | PRO DOC LIMITEE | Tablet | ERYTHROMYCIN STEARATE 250 MG | Cancelled Post Market |
International API supply for ERYTHROMYCIN STEARATE
0 valid EDQM Certificates of Suitability from 0 holders. 5 active FDA Drug Master Files.
Request a quote for ERYTHROCIN LIQ 250